DNA Encoded Libraries DNA encoded libraries are ideal drug delivery tools with respect to its advantages such as DNA Library size, identification of equipment requirements, etc enabling identification of potential molecule with the screening of small organic ligands. A drug is developed with the invention of a molecule and takes around 10-15 years along with heavy investment worth USD 4-10 billion. A small number of chosen molecules are tested for the drug discovery process which often ends up in failure of program. To overcome the complex system many mid-sized and large companies are building in-house DNA encoded libraries. The 210-pages report “ DNA-Encoded Libraries: Platforms and Services Market” features the untapped opportunities that researchers can achieve with DNA- encoded library.
Posts
Prefilled Syringe Packaging It has been three decades that Prefilled Syringe Manufacturers entered the domain and started maintaining chain supply in a prefilled syringe market with a motive to fulfill the requirements of individuals suffering from the chronic disease who require medication on daily basis. The self-injection device such as pen-injectors is divided into two chambers and comes with multiple types of specialty syringes. The 554-pages report ‘Prefilled Syringes Market (5th edition), 2019-2030’ highlights the future opportunities in the device manufacturing and production of prefilled syringe packaging . The report also highlights the major players in the market and the capability of stakeholders engaged in the domain.
Protacs The 357-page report ‘Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics, 2020-2030’ focuses on the small molecule degraders including specific and non-genetic IAP-dependent protein erasers (SNIPERs), proteolysis targeting chimeras ( PROTACs ), lysosome targeting chimeras (LYTACs), endosome targeting chimeras (ENDTACs), epichaperome inhibitors, hydrophobic tags, immuno-modulatory imide drugs (IMiDs), protein homeostatic modulators, selective androgen receptor degraders (SARDs), selective estrogen receptor degraders (SERDs), and specific bromodomain and extra-terminal motif (BET) inhibitors and deubiquitinase (DUB) inhibitors. The report highlights the capabilities of protein degraders and major market players involved in the evaluation. It is worth mentioning that there is no protein-degrader based drug in the market yet. We can expect the therapy to become an extensive part of therapeutic modality in upcoming decade.
Cell Therapy Manufacturing Process The Car-T manufacturing industry has invented over 20-cell therapies and cell therapy manufacturing companies are involved to fulfill the high demand for the technology. Around 500-products are undergoing cell-therapy manufacturing processes . The immense success of the technology has motivated the investors to explore the market resulting in a growing number of product development initiatives. The 502-pages report “ Cell Therapy Manufacturing Market (3rd Edition), 2019-2030” highlights the current market landscape of cell therapy market. It focuses on the major players involved in the development involving both in-house manufacturers and contract manufacturers. To expand the productivity level, several CMOs are opting for acquisitions as well.
Prefilled Syringe Market It has been three decades that Prefilled Syringe Manufacturers entered the domain and started maintaining chain supply in a prefilled syringe market with a motive to fulfill the requirements of individuals suffering from the chronic disease who require medication on daily basis. The self-injection device such as pen-injectors is divided into two chambers and comes with multiple types of specialty syringes. The 554-pages report ‘Prefilled Syringes Market (5th edition), 2019-2030’ highlights the future opportunities in the device manufacturing and production of prefilled syringe packaging. The report also highlights the major players in the market and the capability of stakeholders engaged in the domain.
Ligands DNA encoded libraries are ideal drug delivery tools with respect to its advantages such as DNA Library size, identification of equipment requirements, etc enabling identification of potential molecule with the screening of small organic ligands . A drug is developed with the invention of a molecule and takes around 10-15 years along with heavy investment worth USD 4-10 billion. A small number of chosen molecules are tested for the drug discovery process which often ends up in failure of program. To overcome the complex system many mid-sized and large companies are building in-house DNA encoded libraries. The 210-pages report “ DNA-Encoded Libraries: Platforms and Services Market” features the untapped opportunities that researchers can achieve with DNA- encoded library.
Antibody Drug Conjugates The approval of a number of Antibody Drug Conjugates has resulted in high demand of linker molecule known as Antibody-drug conjugate linker and future opportunities in Antibody Drug Conjugate market. ADCs are categorized as a novel class of therapeutics as the process specifically identify the disease-associated cells and delete them. The therapy derived this ability from lead molecules. The 310-pages report “ Antibody Drug Conjugates: Linker and Conjugation Technologies Market, 2019-2030” highlights the current market landscape of ADCs linker and also provides likely future opportunities in the market. The report also provides an in-depth analysis of the technology based on noteworthy parameters.
Bispecific Antibodies Companies Bispecific Antibody Market holds potential growth due to the presence of promising agents for therapeutic use which can be utilized for the development of next-generation ADCs- Bispecific and Multispecific antibody. With the approval of the first monoclonal antibody, several antibody manufacturing companies marketed the treatment despite its several limitations. With patent expiry and the presence of the aforementioned challenges motivated bispecific antibodies companies to research and develop the next generation of ADCs further eliminating the limitations. The 410-pages report “Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030” features the current market scenario and likely adoption of the above-mentioned therapeutics by next decade. The report also highlights the major market players and their achievements in this domain.